Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 3, 2007, Pages 690-698

  Skala, Marketa ^a   Rosewall, Tara ^b   Dawson, Laura ^a   Divanbeigi, Lorella ^b   Lockwood, Gina ^b   Thomas, Christopher ^b   Crook, Juanita ^a   Chung, Peter ^a   Warde, Padraig ^a   Catton, Charles ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Conformal radiotherapy; Image guided radiotherapy; Late morbidity; Principal component analysis; Prostate carcinoma

Indexed keywords

DOSIMETRY; HISTOLOGY; MEDICAL IMAGING; ONCOLOGY; PRINCIPAL COMPONENT ANALYSIS; RADIOTHERAPY; TUMORS;

CONFORMAL RADIOTHERAPY; IMAGE GUIDED RADIOTHERAPY; LATE MORBIDITY; PROSTATE CARCINOMA;

TOXICITY;

ARTICLE; BLADDER DISEASE; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; ERECTILE DYSFUNCTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM DISEASE; SELF REPORT; TREATMENT PLANNING;

DIAGNOSTIC IMAGING; HUMANS; INCIDENCE; MALE; ONTARIO; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTAL DISEASES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; URINARY BLADDER DISEASES;

EID: 34249306937     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.12.064     Document Type: Article

References (25)

1. Pollack A., Zagars G., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Zietman A., DeSilvio M., Slater J., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
3. Peeters S., Heemsbergen W., van Putten W., et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
4. Hanks G., Hanlon A., Pinover W., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46 (2000) 823-832
5. Dearnaley D., Khoo V., Norman A., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353 (1999) 267-272
6. Zelefsky M., Liebel S., Gaudin P., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Rad Onc Biol Phys 41 (1998) 491-500
7. Litwin M., Hays R., Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 (1995) 129-135
8. Talcott J., Rieker P., Propert K., et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 89 (1997) 1117-1123
9. Nichol A., Chung P., Lockwood G., et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
10. Benk V., Adams J., and Shipley W. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 551-557
11. Boersma L., van den Brink M., Bruce A., et al. Estimations of the incidence of late bladder and rectum complications after high dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Rad Onc Biol Phys 41 (1998) 83-92
12. Storey M., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomised trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
13. Dawson L., Biersack M., Lockwood G., et al. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys 62 (2005) 829-837
14. Crook J., Esche B., and Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspective. Urology 47 (1996) 317-394
15. Chung P., Haycocks T., Brown T., et al. On-line aSI portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 60 (2004) 329-334
16. Wu J., Haycocks T., Alasti H., et al. Portal film analysis of an escalated dose conformal prostatic irradiation protocol using fiducial markers and portal images to confirm target organ and isocentre position. Radiother Oncol 61 (2001) 127-135
17. Michalski J., Purdy J., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46 (2000) 391-402
18. Zelefsky M., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
19. Bhatnagar V., Stewart S., Huynh V., et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 9 (2006) 136-146
20. Vargas C., Yan D., Kestin L., et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys 63 (2005) 141-149
21. Soehn M., Yan D., Liang J., et al. Influence of dose volume histogram (DVH) pattern on rectal toxicity. [Abstract]. Int J Radiat Oncol Biol Phys 63 (2005) S58
22. O'Brien P., Hamilton C., Denham J., et al. Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 75-80
23. Wei J., Dunn R., Litwin M., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
24. Wall M., Rechtsteiner A., and Rocha L. Singular value decomposition and principal component analysis. In: Berrar D., Dubitzky W., and Granzow M. (Eds). A practical approach to microarray data analysis (2003), Kluwer, Norwell, MA
25. Jackson J. A user's guide to principal components (1991), John Wiley & Sons, Hoboken, NJ